Sunday, December 22, 2024

Inogen, announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President, Business Development

Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President, Business Development, effective July 22, 2024. Mr. Smith joins Inogen from Sirtex Medical, where he served as General Counsel and Executive Vice President, Business Development, since 2018.

Mr. Smith brings nearly thirty years of experience to the Company. Prior to joining Sirtex, Kevin served as vice president and associate general counsel at Flexion Therapeutics, focusing on securities requirements, business development, and intellectual property. Previously, he was general counsel for the Danaher Life Sciences Platform. He has also held senior legal leadership positions within Novartis Pharmaceuticals. Before moving in-house, Mr. Smith worked for multinational law firms in New York, Silicon Valley, and London.

Also Read: Lindus Health Launches Bespoke “All-in-One Medical Device CRO” Offering for Medical Device Clinical Trials

Kevin Smith, President and Chief Executive Officer of Inogen, said, “Kevin will be an invaluable addition to our leadership team at Inogen. His extensive experience in the medical device and securities field will play an important role in strengthening our legal team and ensuring Inogen remains an organization based on integrity and compliance.”

Inogen, Inc.  is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its oxygen therapy products widely available allowing patients the chance to remain ambulatory while managing the impact of their disease.

SOURCE: Businesswire

Subscribe Now

    Hot Topics